Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Cancer Cell

Volumn 3, Issue 4, 2003, Pages 347-361

  Pennacchietti, Selma ^a   Michieli, Paolo ^a   Galluzzo, Maria ^a   Mazzone, Massimiliano ^a   Giordano, Silvia ^a   Comoglio, Paolo M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; METHIONINE;

ANOXIA; ARTICLE; CANCER INVASION; CELL CULTURE; CELL MOTION; COMPARATIVE STUDY; FLUORESCENT ANTIBODY TECHNIQUE; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROMOTER REGION; WESTERN BLOTTING; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH;

ANOXIA; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; FLUORESCENT ANTIBODY TECHNIQUE; GENE TRANSFER TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-MET; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0037478437     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00085-0     Document Type: Article

References (97)

1. Aguirre Ghiso J.A., Alonso D.F., Farias E.F., Gomez D.E., de Kier Joffe E.B. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur. J. Biochem. 263:1999;295-304.
2. Andermarcher E., Surani M., Gherardi E. Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev. Genet. 18:1996;254-266.
3. Bardelli A., Longati P., Williams T.A., Benvenuti S., Comoglio P.M. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J. Biol. Chem. 274:1999;29274-29281.
4. Birchmeier W., Brinkmann V., Niemann C., Meiners S., DiCesare S., Naundorf H., Sachs M. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found. Symp. 212:1997;230-240.
5. Blagosklonny M.V. Hypoxia-inducible factor. Achilles' heel of antiangiogenic cancer therapy Int. J. Oncol. 19:2001;257-262.
6. Boccaccio C., Gaudino G., Gambarotta G., Galimi F., Comoglio P.M. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J. Biol. Chem. 269:1994;12846-12851.
7. Boccaccio C., Andò M., Tamagnone L., Bardelli A., Michieli P., Battistini C., Comoglio P.M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 391:1998;285-288.
8. Boix L., Rosa J.L., Ventura F., Castells A., Bruix J., Rodes J., Bartrons R. c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology. 19:1994;88-91.
9. Brinkmann V., Foroutan H., Sachs M., Weidner K.M., Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J. Cell Biol. 131:1995;1573-1586.
10. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
11. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;285-289.
12. Cairns R.A., Kalliomaki T., Hill R.P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61:2001;8903-8908.
13. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer. 2:2002;563-572.
14. Comoglio P.M., Trusolino L. Invasive growth. from development to metastasis J. Clin. Invest. 109:2002;857-862.
15. Crepaldi T., Prat M., Giordano S., Medico E., Comoglio P.M. Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum. J. Biol. Chem. 269:1994;1750-1755.
16. Damert A., Ikeda E., Risau W. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem. J. 327:1997;419-423.
17. Date K., Matsumoto K., Kuba K., Shimura H., Tanaka M., Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 17:1998;3045-3054.
18. Di Renzo M.F., Olivero M., Ferro S., Prat M., Bongarzone I., Pilotti S., Belfiore A., Costantino A., Vigneri R., Pierotti M.A., Comoglio P.M. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene. 7:1992;2549-2553.
19. Di Renzo M.F., Olivero M., Giacomini A., Porte H., Chastre E., Mirossay L., Nordlinger B., Bretti S., Bottardi S., Giordano S.et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1:1995;147-154.
20. Di Renzo M.F., Olivero M., Martone T., Maffe A., Maggiora P., Stefani A.D., Valente G., Giordano S., Cortesina G., Comoglio P.M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene. 19:2000;1547-1555.
21. Folkman J. Angiogenesis research. from laboratory to clinic Forum (Genova). 9(Suppl. 3):1999;59-62.
22. Follenzi A., Bakovic S., Gual P., Stella M.C., Longati P., Comoglio P.M. Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 19:2000;3041-3049.
23. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:1996;4604-4613.
24. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124:1994;619-626.
25. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13:2001;555-562.
26. Gambarotta G., Pistoi S., Giordano S., Comoglio P.M., Santoro C. Structure and inducible regulation of the human MET promoter. J. Biol. Chem. 269:1994;12852-12857.
27. Gambarotta G., Boccaccio C., Giordano S., Andò M., Stella M.C., Comoglio P.M. Ets up-regulates MET transcription. Oncogene. 13:1996;1911-1917.
28. Gerber H.-P., Condorelli F., Park J., Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. J. Biol. Chem. 272:1997;23659-23667.
29. Gherardi E., Gray J., Stoker M., Perryman M., Furlong R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc. Natl. Acad. Sci. USA. 86:1989;5844-5848.
30. Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D., Tamagnone L., Comoglio P.M. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 4:2002;720-724.
31. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
32. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
33. Hannon G.J. RNA interference. Nature. 418:2002;244-251.
34. Harris A.L. Hypoxia-a key regulatory factor in tumor growth. Nature Rev. Cancer. 2:2002;38-47.
35. Höckel M., Vaupel P. Tumor hypoxia. definitions and current clinical, biologic, and molecular aspects J. Natl. Cancer Inst. 93:2001;266-276.
36. Höckel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
37. Höckel M., Schlenger K., Höckel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59:1999;4525-4528.
38. Kimura H., Weisz A., Kurashima Y., Hashimoto K., Ogura T., D'Acquisto F., Addeo R., Makuuchi M., Esumi H. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide. control of hypoxia-inducible factor-1 activity by nitric oxide Blood. 95:2000;189-197.
39. Koochekpour S., Jeffers M., Wang P.H., Gong C., Taylor G.A., Roessler L.M., Stearman R., Vasselli J.R., Stetler-Stevenson W.G., Kaelin W.G. Jr. et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 19:1999;5902-5912.
40. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270:1995;13333-13340.
41. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature. 411:2001;375-379.
42. Liu C., Park M., Tsao M.S. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 7:1992;181-185.
43. Lyon M., Deakin J.A., Mizuno K., Nakamura T., Gallagher J.T. Interaction of hepatocyte growth factor with heparan-sulfate. Elucidation of the major heparan sulfate structural determinants. J. Biol. Chem. 269:1994;11216-11223.
44. Maity A., Solomon D. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Exp. Cell Res. 255:2000;250-257.
45. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal carcinoma. Cancer Cell. 1:2002;247-255.
46. Matsumoto K., Nakamura T. Hgf. its organotrophic role and therapeutic potential Ciba Found. Symp. 212:1997;198-211.
47. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
48. Medico E., Mongiovi A.M., Huff J., Jelinek M.A., Follenzi A., Gaudino G., Parsons J.T., Comoglio P.M. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol. Biol. Cell. 7:1996;495-504.
49. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Buttner M., Rziha H.J., Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18:1999;363-374.
50. Michieli P., Basilico C., Pennacchietti S., Maffe A., Tamagnone L., Giordano S., Bardelli A., Comoglio P.M. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene. 18:1999;5221-5231.
51. Michiels C., Minet E., Michel G., Mottet D., Piret J.P., Raes M. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia. role of MAP kinases IUBMB Life. 52:2001;49-53.
52. Miyazawa K., Shimomura T., Naka D., Kitamura N. Proteolytic activation of hepatocyte growth factor in response to tissue injury. J. Biol. Chem. 269:1994;8966-8970.
53. Montesano R., Matsumoto K., Nakamura T., Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 67:1991;901-908.
54. Morotti A., Mila S., Accornero P., Tagliabue E., Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene. 21:2002;4885-4893.
55. Nakamura T., Teramoto H., Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA. 83:1986;6489-6493.
56. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., Tashiro K., Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 342:1989;440-443.
57. Naldini L., Vigna E., Ferracini R., Longati P., Gandino L., Prat M., Comoglio P.M. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol. Cell. Biol. 11:1991;1793-1803.
58. Naldini L., Tamagnone L., Vigna E., Sachs M., Hartmann G., Birchmeier W., Daikuhara Y., Tsubouchi H., Blasi F., Comoglio P.M. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J. 11:1992;4825-4833.
59. 2-responsive sequences on the tyrosine hydroxylase gene. J. Biol. Chem. 270:1995;23774-23779.
60. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin. a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell. 79:1994;315-328.
61. Oh R.R., Park J.Y., Lee J.H., Shin M.S., Kim H.S., Lee S.K., Kim Y.S., Lee S.H., Lee S.N., Yang Y.M.et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. APMIS. 110:2002;229-238.
62. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16:2002;3074-3086.
63. Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J., Bae J.H., Hong Y.K., Lee K.S.et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 59:1999;307-310.
64. Postovit L.M., Adams M.A., Lash G.E., Heaton J.P., Graham C.H. Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. J. Biol. Chem. 277:2002;35730-35737.
65. Prat M., Crepaldi T., Pennacchietti S., Bussolino F., Comoglio P.M. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J. Cell Sci. 111:1998;237-247.
66. Richard D.E., Berra E., Pouysségur J. Nonhypoxic pathway mediates the induction of Hypoxia-Inducible Factor 1α in vascular smooth muscle cells. J. Biol. Chem. 275:2000;26765-26771.
67. Rofstad E.K., Rasmussen H., Galappathi K., Mathiesen B., Nilsen K., Graff B.A. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62:2002;1847-1853.
68. Rubin J.S., Bottaro D.P., Aaronson S.A. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta. 1155:1993;357-371.
69. Ruco L.P., Ranalli T., Marzullo A., Bianco P., Prat M., Comoglio P.M., Baroni C.D. Expression of Met protein in thyroid tumours. J. Pathol. 180:1996;266-270.
70. Sánchez-Elsner T., Botella L.M., Velasco B., Langa C., Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 277:2002;43799-43808.
71. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 373:1995;699-702.
72. Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., Lubensky I., Neumann H.P., Brauch H., Decker J.et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 18:1999;2343-2350.
73. 2, and the 3 PHDs. how animal cells signal hypoxia to the nucleus Cell. 107:2001;1-3.
74. Seol D.W., Chen Q., Zarnegar R. Transcriptional activation of the hepatocyte growth factor receptor (c-met) gene by its ligand (hepatocyte growth factor) is mediated through AP-1. Oncogene. 19:2000;1132-1137.
75. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
76. Stoker M., Gherardi E. Regulation of cell movement. the motogenic cytokines Biochim. Biophys. Acta. 1072:1991;81-102.
77. Stoker N., Gherardi E., Perryman M., Grey J. Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature. 327:1987;239-242.
78. Sundfor K., Lyng H., Rofstad E.K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer. 78:1998;822-827.
79. Tacchini L., Dansi P., Matteucci E., Desiderio M.A. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis. 22:2001;1363-1371.
80. Takayama H., La Rochelle W.J., Anver M., Bockman D.E., Merlino G. Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc. Natl. Acad. Sci. USA. 93:1996;5866-5871.
81. Trusolino L., Comoglio P.M. Scatter-factor and semaphorin receptors. cell signalling for invasive growth Nature Rev. Cancer. 4:2002;289-300.
82. Trusolino L., Bertotti A., Comoglio P.M. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell. 107:2001;643-654.
83. Uehara Y., Minowa O., Mori C., Shiota K., Kuno J., Noda T., Kitamura N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 373:1995;702-705.
84. Vande Woude G.F., Jeffers M., Cortner J., Alvord G., Tsarfaty I., Resau J. Met-hgf/sf. tumorigenesis, invasion and metastasis Ciba Found. Symp. 212:1997;119-130.
85. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. a review Cancer Res. 49:1989;6449-6465.
86. Vukovic V., Haugland H.K., Nicklee T., Morrison A.J., Hedley D.W. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res. 61:2001;7394-7398.
87. Weidner K.M., Di Cesare S., Sachs M., Brinkmann V., Behrens J., Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 384:1996;173-176.
88. Woodhouse E.C., Chuaqui R.F., Liotta L.A. General mechanisms of metastasis. Cancer. 80:1997;1529-1537.
89. Woolf A.S., Kolatsi-Joannou M., Hardman P., Andermarcher E., Moorby C., Fine L.G., Jat P.S., Noble M.D., Gherardi E. Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros. J. Cell Biol. 128:1995;171-184.
90. Xu Q., Ji Y.S., Schmedtje J.F. Jr. Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. J. Biol. Chem. 275:2000;24583-24589.
91. Yamashita K., Discher D.J., Hu J., Bishopric N.H., Webster K.A. Molecular regulation of the endothelin-1 gene by hypoxia. J. Biol. Chem. 276:2001;12645-12653.
92. Yanagita K., Matsumoto K., Sekiguchi K., Ishibashi H., Niho Y., Nakamura T. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J. Biol. Chem. 268:1993;21212-21217.
93. Yang Y., Spitzer E., Meyer D., Sachs M., Niemann C., Hartmann G., Weidner K.M., Birchmeier C., Birchmeier W. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J. Cell Biol. 131:1995;215-226.
94. Young S.D., Hill R.P. Effects of reoxygenation of cells from hypoxic regions of solid tumors. anticancer drug sensitivity and metastatic potential J. Natl. Cancer Inst. 82:1990;338-339.
95. Young S.D., Marshall R.S., Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA. 85:1988;9533-9537.
96. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 295:2002;1526-1528.
97. Yuan Y., Hilliard G., Ferguson T., Millhorn D.E. Cobalt inhibits the interaction between hypoxia inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia inducible factor-alpha. J. Biol. Chem. in press:2003.